ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a small molecule inhibitor targeting nuclear factor erythroid 2-related factor 2 (NRF2) with an IC₅₀ of 1.9 μM, demonstrating potent and selective NRF2 pathway suppression in non-small cell lung cancer (NSCLC) models (APExBIO). In vivo, ML385 reduces NSCLC tumor growth and metastatic potential, especially when combined with chemotherapeutics such as carboplatin (Zhou et al., 2024). ML385 enables mechanistic dissection of NRF2-dependent antioxidant, detoxification, and multidrug resistance pathways. The compound is insoluble in ethanol and water, but dissolves at ≥13.33 mg/mL in DMSO; recommended storage is at -20°C. ML385’s selectivity and robust benchmarks make it a preferred reagent for cancer and oxidative stress research, as detailed below.

Biological Rationale

NRF2 is a transcription factor that coordinates the expression of genes involved in antioxidant response, detoxification, and cell survival. Upregulation of NRF2 is frequently observed in cancer cells and is associated with resistance to chemotherapy and radiotherapy (Zhou et al., 2024). Inhibition of NRF2 can sensitize tumor cells to oxidative stress and cytotoxic agents. ML385 provides researchers with a selective tool to block NRF2 activity and examine downstream effects on gene expression, oxidative stress response, and ferroptosis. The product is extensively used in studies of non-small cell lung cancer (NSCLC), where NRF2-mediated resistance is prominent (APExBIO).

Mechanism of Action of ML385

ML385 inhibits NRF2 by binding directly to the transcription factor’s Neh1 DNA-binding domain, thereby preventing NRF2 from associating with antioxidant response element (ARE) sequences in target gene promoters (Zhou et al., 2024). This leads to a dose- and time-dependent downregulation of NRF2-dependent genes, such as NAD(P)H quinone dehydrogenase 1 (NQO1), heme oxygenase-1 (HO-1), and glutamate-cysteine ligase catalytic subunit (GCLC). ML385 does not significantly inhibit other transcription factors at concentrations below 10 μM, supporting its selectivity profile (APExBIO).

Evidence & Benchmarks

• ML385 inhibits NRF2 transcriptional activity with an IC₅₀ of 1.9 μM in cell-based reporter assays (APExBIO).
• In A549 NSCLC cells, ML385 treatment decreases expression of NRF2 downstream genes (NQO1, HO-1, GCLC) in a dose-dependent manner (Zhou et al., 2024, https://doi.org/10.18632/aging.205693).
• ML385 (100 mg/kg/day, intraperitoneal) reduces tumor growth and metastasis in NSCLC mouse models, with enhanced effects when combined with carboplatin (Zhou et al., 2024, https://doi.org/10.18632/aging.205693).
• ML385 enhances sensitivity of cancer cells to oxidative stress, ferroptosis, and standard chemotherapeutics (Zhou et al., 2024, https://doi.org/10.18632/aging.205693).
• ML385 is insoluble in water and ethanol, but soluble at ≥13.33 mg/mL in DMSO; storage at -20°C is recommended to maintain compound stability (APExBIO).

For a scenario-driven practical guide, see ML385 (SKU B8300): Precision NRF2 Inhibition for Cancer and Oxidative Stress Research, which expands on data-backed solutions for laboratory challenges. This article further details quantitative in vivo benchmarks and mechanistic selectivity not covered in that piece.

Applications, Limits & Misconceptions

ML385 is primarily used in research on:

• NRF2 signaling pathway inhibition in cancer and oxidative stress models
• Dissection of NRF2-dependent transcriptional programs
• Investigation of drug resistance mechanisms in NSCLC and other cancers
• Combination studies with chemotherapeutics (e.g., carboplatin)
• Modulation of ferroptosis and assessment of antioxidant responses

For detailed mechanistic insights and emerging experimental strategies, see ML385: Unraveling NRF2 Inhibition in Cancer and Oxidative Stress, which focuses on innovative applications; the present article provides updated in vivo combination data and solubility guidance.

Common Pitfalls or Misconceptions

• ML385 activity is not retained in aqueous or ethanol-based buffers; DMSO is required for dissolution and delivery.
• It is not a pan-transcription factor inhibitor; selectivity is limited to NRF2 at recommended concentrations (<10 μM).
• Long-term storage of ML385 solutions, even at -20°C, can result in compound degradation; prepare fresh aliquots for reproducibility.
• ML385 does not reverse established chemoresistance in all cancer models; efficacy must be validated per context.
• It is not approved for clinical or diagnostic use; for research applications only.

For best practices in experimental optimization, see ML385: Selective NRF2 Inhibitor for Cancer Research and Oxidative Stress Models. This article clarifies updated storage, solubility, and combination therapy parameters not fully detailed in the prior guide.

Workflow Integration & Parameters

• Preparation: Dissolve ML385 in DMSO to at least 13.33 mg/mL. Avoid water or ethanol as solvents (APExBIO).
• Cell-based assays: Typical working concentrations: 1–10 μM, validated in A549 and other NSCLC cell lines (Zhou et al., 2024).
• In vivo studies: Intraperitoneal injection at 100 mg/kg/day in mouse models; monitor for compound stability and vehicle control (Zhou et al., 2024).
• Storage: Powder at -20°C; avoid repeated freeze-thaw cycles for dissolved aliquots (APExBIO).

For protocol optimization and validated assay workflows, refer to the ML385 product page (SKU B8300) from APExBIO for technical datasheets and batch-specific documentation.

Conclusion & Outlook

ML385 is a robust, selective NRF2 inhibitor, enabling targeted interrogation of NRF2-driven pathways in cancer and oxidative stress research. Its well-characterized mechanism, high selectivity, and reproducible in vivo efficacy underpin its status as a reference tool for dissecting NRF2-mediated resistance and redox homeostasis. For future directions, ongoing studies will clarify ML385’s role in combination regimens and expand its use across diverse tumor types and oxidative injury models. Researchers are encouraged to consult APExBIO’s technical resources and cross-reference emerging literature for optimal study design.